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Introduction
Globally the numbers of overweight, obese and severely obese people are 
increasing rapidly. High incidences of obesity and overweight have been 
documented for the South African population (Table Ia and Ib). Although 
polygenetic factors play an important role in obesity, environmental 
factors should also be considered. A sedentary occupation and lifestyle 
with easy access to energy dense foods is a major contributor to the 
obesity epidemic. For patients with a BMI > 40 kg/m2, who have failed 
to successfully lose weight, bariatric surgery is a treatment option. 
This surgical intervention can achieve long-term sustained weight loss 
and often induces resolution of comorbidities such as diabetes, sleep 
apnoea, hyperlipidaemia and hypertension (Table II).1
Venous thromboembolism (VTE) may occur after bariatric surgery which 
can cause significant morbidity and mortality. Evidence-based regimens 
for VTE prophylaxis in bariatric and metabolic surgery have resulted in 
some controversy. Recently the American College of Chest Physicians 
(8th edition) published new guidelines on perioperative management 
of antithrombotic therapy.2 Both the obese patient and the procedure 
itself have risks. When looking at VTE rates post major abdominal 
surgery, bariatric surgery has the lowest rate and splenectomy the 
highest.3
46% of the world’s 400 million obese people are from the developing 
world.4
Surgical risk
The positive pressure during laparoscopic inflation has been associated 
with oxidative stress during surgery which, in turn, will cause endothelial 
dysfunction and platelet aggregation. The position of the patient, 
tilted feet down to 15°, as well as the duration of the operation, both 
contribute to decreased blood flow. The duration is influenced by the 
type of surgery performed, e.g. laparoscopic gastric banding usually 
being the quickest and thus with the lowest risk of VTEs.
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Table I(a): South African childhood/adolescent obesity  
(National Representative Study)
Overweight 20.1 % urban children
15.8 % tribal children
10.8% children on farms
Youth risk behaviour study (YRBS) Overweight: 
17 % overweight
4 %  obese 




10 % overweight 
1 %  obese
Table I(b): Prevalence data in South African population
Economically Active Adult Study Meta-analysis of studies in South Africa
Overweight/obese Obese
White men  56.4% ± 20 %
White women                   42.2% ± 24 %
Black men                     49.3% ±  8 %
Black women                   74.6% ± 44 %
Asian men                    35.5 % ±  9 %
Asian women                  37.0 % ± 22 %
Mixed ancestry men             45.7 % ±  8 %
Mixed ancestry women          66.0 % ± 28 %









Diabetes 48 84 99
Dyslipidaemia 59 97 99
Hypertension 43 68 83
Sleep apnoea 95 80 92
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Patient risk factors 
Adipose tissue is one of the main sources of inflammatory mediators, 
including interleukin-6. This cytokine stimulates platelet-aggregating 
factor-1(PAF-1). Plasminogen activator inhibitor-1 levels are increased 
in obesity partly due to increased gene expression in the adipocytes. In 
addition, levels of circulating antithrombin levels are low. A sedentary 
lifestyle and right cardiac insufficiency also contribute to decreased 
venous flow. Overall, obesity is a prothrombotic condition. 
There are several other factors that have to be considered when 
attempting to stratify risk for VTE during bariatric surgery: 
Frezza et al5 indicate that patients are considered high risk if they have:
• Heart failure, a BMI ≥ 50 kg/m2 
• History of a previous thrombotic event or previous pelvic surgery
Gonzalez et al6 identified a higher risk in patients:
• Older than 50 years
• A history of deep vein thrombosis and/or smoking 
• In the presence of an anastamotic leak, revisional or open surgery 
No association was documented of increased risk for VTEs with gender, 
higher BMI, or with comorbidities such as sleep apnoea, hypertension, 
diabetes and myocardial infarction.
Non-pharmacological prophylaxis
There is no consensus on the best prophylactic regimen for VTEs 
in bariatric surgery patients. Debated issues include the type of 
anticoagulant prescribed, use of unfractionated heparin, low-molecular-
weight heparin (LMWH) vs. warfarin, as well as dosage and duration 
of therapy. It is agreed that patients should be mobilised as soon as 
possible, usually within 10–12 hours after surgery. Most groups will 
use calf-length pneumatic compression devices which are fitted and 
started before anaesthesia induction until mobilisation. These devices 
inflate and compress on average every 40 seconds to stimulate lower 
limb blood flow. Intermittent pneumatic compression has been found 
to increase venous velocity and stimulate endogenous fibrinolysis.7 Its 
effect appears to be somewhat lower in post-thrombotic veins. Elastic 
stockings can also be worn for some time after surgery. Clements et 
al8 showed that, in patients without a history of VTE, a short operating 
time (mean 106 minutes), ambulation on day of surgery and calf-length 
pneumatic compression devices gave adequate prophylaxis with a low 
rate of bleeding complications. 
Pharmacological prophylaxis
Bariatric centres of excellence have an anticoagulation protocol that 
includes subcutaneous LMWH. Several studies have looked at different 
heparins and different dosages. The BAFLUX study9 evaluated the 
pharmacodynamic parameters of two doses of the LMWH parnaparin. 
Anti-factor Xa levels were measured on days 0, 4 and 6 postsurgery. 
A dose of 4 250 IU/day was found adequate to keep anti-Xa levels 
between 0.1–0.4 IU/mL. Higher doses increased anti-Xa levels and 
could lead to increased rates of bleeding. Simone et al10 looked at two 
doses of enoxaparin, 40 mg and 60 mg, given 12 hourly and the effect 
was monitored with anti-Xa levels. With 40 mg, 50% of patients failed 
to meet the therapeutic level and no patient was super-therapeutic. It 
is, therefore, possible that a dose of 40 mg may not be enough and 
the LMWH dose should be titrated until anti-Xa levels are in range. The 
timing of chemoprophylaxis administration varies considerably from 
three days before surgery until 21 days after, depending on extremes 
of risk.
Inferior vena cava filters
In the group of super-super morbidly obese patients (BMI > 60), there 
is an international trend to fit an inferior vena cava (IVC) filter prior 
to operation.11 Criteria for IVC filters may vary in different centres 
to include patients at a BMI > 60 kg/m2 or, alternatively, at a weight 
> 250 kg. Patients with BMI < 60 considered at extremely high risk 
for VTEs may also be advised to have an IVC filter fitted. These would 
include patients with a previous pulmonary embolus or ileofemoral 
deep vein thrombosis, a documented hypercoaguable state, significant 
venous stasis or increased right heart pressures (> 40 mmHg).
Recommendations
Screening
There have been some reports that showed an increase in thrombophilias 
in the obese patients compared to the non-obese.12 However, it is not 
considered cost effective to do a full thrombotic profile in every patient. 
It is important to note on the history if there has been a prior deep 
vein thrombosis or pulmonary embolism. If there were no obvious 
precipitating causes for this event, then a thrombophilia screen can 
be considered. This screen cannot be performed on patients who are 
on long-term warfarin therapy. Preoperative factor Xa levels should be 
measured as a baseline marker.
Prophylaxis
Subcutaneous LMWH is the easiest to administer. The dose is usually: 
enoxaparin 40–60 mg daily or parnaparin 4250 IU/day, with the first 
dose administered the day before surgery and continuing intra- and 
postoperatively for a minimum time period of 5–7 days. It is possible 
that in obese patients a dose of 40 mg will not always be adequate, and 
60 mg may be needed. Anti-Xa levels need to be measured to determine 
the accuracy of the administered dose. A level between 0.1–0.4 IU/mL 
is considered therapeutic. Anti-Xa can be measured on days 0, 3 and 7 
postoperatively. Contraindications to anticoagulation would be allergy to 
this class of drugs, heparin induced thrombocytopaenia, a coagulation 
disturbance and excessive bleeding or any clinical concern for high risk 
of bleeding from other organ sites.
General measures
It is important to review the individual patient’s risk profile and minimise 
it where possible. Contraceptive therapy can be discontinued 10 days 
prior to surgery and for 10–21 days postoperatively in women at high 
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risk (i.e. one cycle). Women taking hormone replacement therapy and at 
low risk for thromboembolism may not have to discontinue for longer 
than the period of immobilisation. Smokers should be advised to quit 
smoking at least eight weeks prior to surgery before the operation and 
advised to stop permanently thereafter.
Conclusion
Bariatric surgery remains the most effective means of treating severe 
obesity. The number of severely obese patients is increasing and, 
consequently, more people are seeking bariatric surgery. In the United 
States between 1998 and 2007, the number of bariatric procedures 
increased 15-fold. VTE remains the most worrying complication. A full 
risk profile assessment should be done on history. In patients with a 
history of VTE not previously investigated, a thrombotic profile should 
be done. 
• It is advised that a baseline anti-Xa level should be measured.
• LMWH can be started the day before surgery and continued intra- 
and postoperatively. 
• Enoxaparin 40 mg daily is most commonly used and can be titrated 
against anti-Xa levels if indicated .
• Most patients need to continue with anticoagulation for 7–21 days 
depending of individual risk assessment. 
• In patients with a very high risk profile for VTEs, LMWH should be 
continued for a minimum of three weeks and possibly for up to six 
weeks.  
• Before theatre, elastic stockings and compression devices must be 
fitted until the patient is fully mobilised.  
• Mobilisation should start within 12 hours if no operative 
complications occur.
• In patients weighing more than 250 kg, an inferior vena cava filter 
can be fitted. 
Available evidence to date suggests that adherence to guidelines 
and recommendations will improve, but not necessarily eliminate the 
incidence of VTE.
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